Prostate cancer (PCa) is the most common neoplasia among men in developed countries and a leading cause of cancer-related morbidity and mortality.
PCa is a very heterogeneous disease, both clinically and biologically. Currently, it is difficult to stratify patients into risk groups that entail different disease management. Therefore, a personalized view of this disease is mandatory, through the development of new and more accurate biomarkers that may help clinicians to stratify patients according to threat that PCa poses for each patient. Hence, this review focuses on recent developments of molecular and immunohistochemical biomarkers for PCa risk stratification that might enable a personalized approach to PCa patients. However, despite the increasing amount of available data, there is also an urgent need to translate the most promising biomarkers for clinical use through large multicenter validation trials. Ultimately, these will contribute for an improved clinical management of PCa patients.
Written by:
Costa-Pinheiro P, Henrique R, Jerónimo C. Are you the author?
Cancer Biology and Epigenetics Group - Research Center of Portuguese Oncology Institute - Porto (CI-IPOP), LAB 3, F Building, 1st floor, Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.
Reference: Expert Rev Anticancer Ther. 2014 Aug 22:1-10.
doi: 10.1586/14737140.2014.952288
PubMed Abstract
PMID: 25148431